Pinealon is a lab-made peptide studied for nerve-cell responses to oxidative stress, when reactive molecules strain cells. Most evidence is from cells and rats; small human reports leave major gaps. It is coming soon to Promise.
Coming soon
You are on the list. We will email you when Pinealon becomes available — and nothing else. Joining is not a medical request, and no prescription has been issued.
That did not go through. Check the address and try again.
Pinealon is coming soon to Promise. Add your email and we'll let you know when visits open.
A licensed provider reviews every request; not everyone qualifies.
Every treatment gets its own online clinical questionnaire — your history, medications, and goals.
A real person goes through your history and takes the time to get it right before anything is decided.
If a treatment isn't right for your history, you'll hear that plainly. That review is the whole point.
Made for your prescription by a licensed U.S. pharmacy and shipped in temperature-safe packaging.
Your care team checks in after it arrives. Adjust with your provider, or cancel at any time.
Pinealon is easy to find online and hard to trust there. Promise works the way medicine is supposed to work — a clinician decides, a licensed pharmacy fills, and someone stays accountable to you.
Prescribed for you specifically, after a real look at your health history — never pulled off a shelf.
Your prescription is compounded for you by a licensed U.S. pharmacy — not a mystery vial from an unregulated website.
Temperature-safe shipping, follow-up check-ins, and a care team that answers — before and after your medication arrives.
A three-amino-acid peptide studied around nerve-cell responses to oxidative stress, when reactive molecules strain a cell's defenses. The strongest direct work is in cells and rats.
Cell and rat studies outweigh the small human reports. The available evidence does not establish a clinical benefit or a dependable picture of long-term safety.
When visits open, a provider will review your history alongside the research limits. A prescription will depend on that review, and the provider may decline.
Pinealon is a short, lab-made peptide studied for how nerve cells respond to oxidative stress — when reactive molecules strain a cell's defenses. Most direct work is in cells and rats. Small human reports exist, but they do not establish what it does for memory or how safe it is in people.
Pinealon is coming soon to Promise — add me to the list.
Peptides are short chains of amino acids, the building blocks of proteins. This one has three: glutamic acid, aspartic acid and arginine. Papers often write that sequence as Glu-Asp-Arg or EDR. Those are names for the same molecule.
It comes from Vladimir Khavinson's St. Petersburg research group, which also worked on Epithalon. That shared history is not a reason to swap the names or borrow claims from one molecule for the other.
The name can be confusing. The authors of a 2011 cell study say the peptide was made in a lab after its makers analyzed the amino acids in extracts of cattle brain. The same three-amino-acid sequence is the most common one in cortexin, a peptide preparation from the cortex, the brain's outer layer. So its story runs through brain research, not through extracts of the pineal gland.
The research centers on what happens inside cells under stress. In the 2011 experiments, scientists studied nerve cells taken from rats, rat immune cells and a lab-grown cell line. They measured reactive molecules, cell death and cell signaling. In those laboratory preparations, the authors reported fewer reactive molecules and less cell death.
A change measured in a dish does not show that a person will think or feel differently. It also leaves questions about what happens elsewhere in the body and with longer exposure. The proposed mechanism is still being studied.
In a 2012 rat study of stress before birth, researchers raised levels of a blood substance called homocysteine in pregnant rats. They later measured learning tasks and how the offspring's nerve cells handled oxidative stress. The authors reported better learning-task performance in that model, alongside nerve-cell findings. This narrow pregnancy model cannot establish clinical outcomes for adults.
Human data exist, but they are limited. A 2015 Russian-language report describes thirty-two adults with several chronic illnesses and pre-existing brain disorders. Researchers examined Pinealon and another short peptide. The abstract does not describe random assignment or a placebo comparison, where participants receive an inactive preparation.
The authors reported changes in indicators they used to estimate biological age. They also reported pro-oxidant activity, meaning activity that adds to oxidative stress. They interpreted a change in blood tests as significant suppression of blood-cell formation. The abstract does not separate all findings by peptide, so it cannot tell us which preparation accounts for each finding.
These reports leave the evidence too limited to establish a clinical benefit or long-term safety. A small study's account of laboratory markers cannot answer the larger question of what happens to patients over time. Unknowns about interactions with other medicines also matter when a provider weighs a request.
The formulation Promise will offer is not FDA-approved. It will be compounded for an individual patient by a pharmacy. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality.
A licensed provider may still prescribe — that decision is between you and your doctor.
They are different molecules from the same research tradition. Epithalon has four amino acids and comes from that group's pineal-gland research. Its name also appears as Epitalon in scientific papers. This page concerns the three-amino-acid EDR sequence, whose development was linked to brain extracts.
The similar names hide different sequences and research histories. A finding about one cannot serve as evidence for the other, and one is not a substitute for the other.
Promise places this compound in Brain Health & Memory because of its research focus. That category does not promise better memory, intelligence or concentration. Semax has its own page there and is a different, seven-amino-acid peptide. Its research cannot fill the evidence gaps for this molecule.
When visits open, the process will begin with an intake questionnaire written for Pinealon. It will ask about your health history, current medicines and supplements, and the reason for your request.
A licensed provider will weigh the research limits alongside your history. They may ask for more information, prescribe, or decline. If prescribed, a licensed U.S. pharmacy will compound and dispense the medication.
Your provider sets any protocol; Promise does not publish dosing. Follow-up check-ins from your care team will be part of the plan, so questions and concerns can go back to a clinician.
Joining the waitlist requests an email when visits open. The medical review will happen later; joining the list does not reserve a prescription.
Pinealon is a synthetic peptide made of three amino acids, the building blocks of proteins: glutamic acid, aspartic acid and arginine. Papers also call it Glu-Asp-Arg or EDR. It is studied for nerve-cell responses to oxidative stress, when reactive molecules strain a cell's defenses. Most direct evidence comes from cells and rats, with limited human reports.
Yes. When visits open, Pinealon will be prescribed by a licensed provider after a review of your health history and compounded for you by a licensed U.S. pharmacy. It will not be a product labeled for laboratory use. A prescription will depend on whether the provider decides it is appropriate for you.
A visit does not guarantee a prescription. Once visits open, a licensed provider will review your health history, medications and reason for the request. They may ask for more information or decide that Pinealon is not appropriate. A decline is a possible outcome of that review.
No. Pinealon is not FDA-approved, and no FDA-approved product contains it. The formulation Promise will offer is a compounded medication, which is not reviewed by the FDA for safety, effectiveness, or quality. A licensed provider's decision to prescribe does not change that regulatory status or establish a clinical benefit.
Not yet. Pinealon is coming soon to Promise — add me to the list on this page and we'll email you when visits open. Joining the list requests that notification; it does not start a medical visit or reserve a prescription. The provider review will take place after visits open.
Pinealon and Epithalon are different peptides from the same research tradition. Pinealon has three amino acids and is studied mainly around nerve-cell stress. Epithalon has four amino acids and came from research on pineal-gland extracts. Similar names do not make them interchangeable, and findings for one do not establish what the other does in people.
Most direct evidence concerns cell cultures and rats. Small human reports also exist, including one examining Pinealon and another peptide in adults with chronic illnesses and brain disorders. That abstract does not describe random assignment or a placebo comparison. Its authors interpreted blood-cell markers as significant suppression of blood-cell formation. These findings cannot establish a clinical benefit or long-term safety, or separate all risks by peptide.
Products sold online without a prescription may be labeled for laboratory use and may come without a provider reviewing your history or a pharmacy preparing medication for you. When visits open, Promise's process will require a licensed provider's decision, a patient-specific prescription when appropriate, a licensed U.S. pharmacy and follow-up check-ins.
Other Brain Health & Memory options a provider may consider.
Brain Health & Memory
Two Russian-developed peptides prescribed together: Semax, an ACTH fragment studied around BDNF expression, and Selank, a tuftsin analog studied around anxiolytic signaling.
Requires an online medical evaluation. Prescribed only when a licensed provider determines it's appropriate.
Type a treatment, a goal, or a question.